WallStSmart

Boston Scientific Corp (BSX)vsCytosorbents Crp (CTSO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 56317% more annual revenue ($21.00B vs $37.22M). BSX leads profitability with a 17.5% profit margin vs -48.9%. BSX earns a higher WallStSmart Score of 72/100 (B).

BSX

Strong Buy

72

out of 100

Grade: B

Growth: 7.3Profit: 7.0Value: 6.7Quality: 5.5
Piotroski: 5/9Altman Z: 1.78

CTSO

Avoid

24

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 5.0Quality: 5.0
Piotroski: 4/9Altman Z: -9.11
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXOvervalued (-10.0%)

Margin of Safety

-10.0%

Fair Value

$39.07

Current Price

$42.98

$3.91 premium

UndervaluedFair: $39.07Overvalued

Intrinsic value data unavailable for CTSO.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX6 strengths · Avg: 8.2/10
Market CapQuality
$62.29B9/10

Large-cap with strong market position

PEG RatioValuation
0.608/10

Growing faster than its price suggests

P/E RatioValuation
17.5x8/10

Attractively priced relative to earnings

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Operating MarginProfitability
22.9%8/10

Strong operational efficiency at 22.9%

Free Cash FlowQuality
$1.28B8/10

Generating 1.3B in free cash flow

CTSO1 strengths · Avg: 10.0/10
Debt/EquityHealth
-35.0710/10

Conservative balance sheet, low leverage

Areas to Watch

BSX1 concerns · Avg: 4.0/10
Altman Z-ScoreHealth
1.784/10

Distress zone — elevated risk

CTSO4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.2%4/10

0.2% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$20.20M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-540.1%2/10

ROE of -540.1% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, P/E Ratio. Profitability is solid with margins at 17.5% and operating margin at 22.9%. PEG of 0.60 suggests the stock is reasonably priced for its growth.

Bull Case : CTSO

The strongest argument for CTSO centers on Debt/Equity.

Bear Case : BSX

The primary concerns for BSX are Altman Z-Score.

Bear Case : CTSO

The primary concerns for CTSO are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

BSX profiles as a mature stock while CTSO is a turnaround play — different risk/reward profiles.

CTSO carries more volatility with a beta of 1.34 — expect wider price swings.

BSX is growing revenue faster at 7.5% — sustainability is the question.

BSX generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

BSX scores higher overall (72/100 vs 24/100), backed by strong 17.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Cytosorbents Crp

HEALTHCARE · MEDICAL DEVICES · USA

Cytosorbents Corporation, a critical care focused immunotherapy company, is dedicated to the research, development and commercialization of medical devices with its blood purification technology platform incorporating proprietary adsorbent and porous polymer technology. The company is headquartered in Monmouth Junction, New Jersey.

Want to dig deeper into these stocks?